Evidence map›Paper›PMID 36233222›Full record

ReviewInternational journal of molecular sciences2022

Selecting for CRISPR-Edited Knock-In Cells.

Nina Reuven, Yosef Shaul

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Efficient tagging of endogenous proteins in human cell lines for structural studies by single-particle cryo-EM.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  10. Enrichment strategies to enhance genome editing.Journal of biomedical science · 2023
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nina ReuvenDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0003-1569-3818
Yosef ShaulDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0002-0545-6512

Funding

CSRD VA 1F.I.R.S.T. Individual Grants 2206/19Israel Science Foundation 1591/15
6 · The paper itself

Abstract

CRISPR technology affords a simple and robust way to edit the genomes of cells, providing powerful tools for basic research and medicine. While using Cas9 to target a genomic site is very efficient, making a specific mutation at that site is much less so, as it depends on the endogenous DNA repair machinery. Various strategies have been developed to increase the efficiency of knock-in mutagenesis, but often the desired cells remain a small percentage of the total population. To improve efficiency, strategies to select edited cells have been developed. In some applications, a selectable foreign gene is linked directly to the gene of interest (GOI). Alternatively, co-editing, where the GOI is edited along with a selectable gene, enriches the desired cells since the cells that successfully edited the selectable gene are likely to have also edited the GOI. To minimize perturbations of the host genome, "scarless" selection strategies have been developed, where the modified cells are mutated solely in the GOI. In this review, we will discuss strategies employed to improve specific genome editing in mammalian cells, focusing on ways to select successfully edited cells.

Indexed as

CRISPR-Cas SystemsGene EditingAnimalsDNA RepairGenomeMammalsco-editingCRISPRgenome editingHDR-dependent editingscarless selection

Identifiers

PMID36233222
PMCPMC9569436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.